SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line

Bellarosa,Daniela; Bressan,Alessandro; Bigioni,Mario; Parlani,Massimo; Maggi,Carlo  Alberto; Binaschi,Monica

doi:10.3892/ijo.2012.1551

SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line

Authors:
- Daniela Bellarosa
- Alessandro Bressan
- Mario Bigioni
- Massimo Parlani
- Carlo Alberto Maggi
- Monica Binaschi
View Affiliations

Affiliations: Department of Pharmacology, Menarini Ricerche, Ι-00040 Pomezia, Italy, Menarini Ricerche, Ι-50131 Florence, Italy
Published online on: July 13, 2012 https://doi.org/10.3892/ijo.2012.1551
Pages: 1486-1494

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

HDAC inhibitors (HDACis) represent a class of anticancer agents including suberoylanilide hydroxamic acid (SAHA, Vorinostat), which has shown a strong antitumor effect, both in vitro and in vivo. Induction of apoptotic genes is an important pathway of SAHA cytotoxic mechanism of action and it has been largely described that SAHA induces sensitization of cell death receptor-resistant breast cancer cells to apoptosis. In this study, we investigated the activation of some apoptotic genes which could be responsible for the in vivo antitumor potency of SAHA in a model of human breast cancer. We found that the apoptotic gene pattern induced by SAHA in the MDA-MB-231 cell line involves the upregulation of some molecules belonging to the TNF superfamily. In particular, we demonstrated that the upregulation of the CD137 receptor/ligand system correlates with a synergistic cytotoxic effect when MDA-MB-231 cells are treated with the combination of SAHA and soluble CD137 receptor. To our knowledge, this is the first study to indicate that this member of the TNF superfamily, CD137, is modulated by SAHA treatment in breast cancer cells, suggesting that the combination of SAHA with this TNF-related receptor could be a new therapeutic approach for the treatment of tumors.

View Figures

View References

1	Grunstein M: Histone acetylation in chromatin structure and transcription. Nature. 389:349–352. 1997. View Article : Google Scholar : PubMed/NCBI
2	Glass CK and Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:121–141. 2000.PubMed/NCBI
3	Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S and Pelicci PG: Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature. 391:815–818. 1998.
4	Garcia-Manero G, Yang H, Bueso-Ramos C, et al: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 111:1060–1066. 2008.
5	Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C and Frankel SR: Phase II trial of the histone deacetylase inhibitor (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 26:81–87. 2008. View Article : Google Scholar : PubMed/NCBI
6	Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
7	Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P and Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 12:634–642. 2006. View Article : Google Scholar : PubMed/NCBI
8	Bertino E and Otterson GA: Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs. 20:1151–1158. 2011. View Article : Google Scholar : PubMed/NCBI
9	Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, Lo Russo P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP and Egorin MJ: Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol. 28:4507–4512. 2010. View Article : Google Scholar
10	Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA and Richon VM: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA. 99:11700–11705. 2002. View Article : Google Scholar : PubMed/NCBI
11	Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B and Richon VM: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res. 22:1497–1504. 2002.PubMed/NCBI
12	Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M and Sakai T: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/ APO2-L in human malignant tumor cells. Oncogene. 23:6261–6271. 2004. View Article : Google Scholar
13	Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P and Bhalla K: Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 64:2580–2589. 2004. View Article : Google Scholar
14	Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63:7291–7300. 2003.PubMed/NCBI
15	Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ and Lee JS: The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene. 23:1724–1736. 2004.PubMed/NCBI
16	Licznar A, Caporali S, Lucas A, Weisz A, Vignon F and Lazennec G: Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor. FEBS Lett. 553:445–450. 2003. View Article : Google Scholar : PubMed/NCBI
17	Srivastava RK, Kurzrock R and Shankar S: MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 9:3254–3266. 2010. View Article : Google Scholar
18	Page B, Page M and Noel C: A new fluorimetric assay for cytotoxicity measurements in vitro. Int J Oncol. 3:473–476. 1993.PubMed/NCBI
19	Workman P, Aboagye EO, Balkwill F, et al: Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 102:1555–1577. 2010. View Article : Google Scholar : PubMed/NCBI
20	Plowman J, Dykes DJ, Melinda H, Simpson-Hellen L and Alley MC: Human tumor xenograft models in NCI drug development. Anticancer Drug Development Guide. Teicher BA: Humana Press; Totowa, NJ: pp. 101–126. 1997, View Article : Google Scholar
21	Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST and van Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1415–1420. 1994.PubMed/NCBI
22	Livak KJ: ABI Prism 7700 Sequence Detection System. User Bulletin No. 2. PE Applied Biosystems AB website, Bulletin Reference 4303859B 77802-002,. 1997.
23	Archer SY, Johnson J, Kim HJ, Ma Q, Mou H, Daesety V, Meng S and Hodin RA: The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/ WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol. 289:G696–G703. 2005.
24	Hellebrekers DM, Melotte V, Viré E, Langenkamp E, Molema G, Fuks F, Herman JG, van Criekinge W, Griffioen AW and van Engeland M: Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 67:4138–4148. 2007. View Article : Google Scholar : PubMed/NCBI
25	Kim HR, Kim E-J, Yang S-H, Jeong E-T, Park C, Lee J-H, Youn M-J, So H-S and Park R: Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway. Exp Mol Med. 38:616–624. 2006. View Article : Google Scholar : PubMed/NCBI
26	Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD and Srivastava RK: Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther. 8:1596–1605. 2009. View Article : Google Scholar
27	Vire B, De Walque S, Restouin A, Olive D, van Lint C and Collette Y: Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. PLoS One. 4:e70852009. View Article : Google Scholar : PubMed/NCBI
28	Sun Y, Chen JH and Fu Y: Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol Immunol. 1:31–36. 2004.PubMed/NCBI
29	Shao Z and Schwarz H: CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol. 89:21–29. 2011. View Article : Google Scholar : PubMed/NCBI
30	Gullo C, Koh LK, Pang WL, Ho KT, Tan SH and Schwarz H: Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. PLoS One. 5:e108452010. View Article : Google Scholar : PubMed/NCBI
31	Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC and Anderson KC: Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 64:2846–2852. 2004. View Article : Google Scholar : PubMed/NCBI
32	Yu SE, Park SH and Jang YK: Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer. Mol Cells. 29:217–221. 2010. View Article : Google Scholar : PubMed/NCBI
33	Dimberg J, Hugander A and Wagsater D: Expression of CD137 and CD137L in colorectal cancer patients. Oncol Rep. 15:1197–1200. 2006.PubMed/NCBI
34	Nicolin V and Narducci P: Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. Acta Histochem. 112:1189–1192. 2010. View Article : Google Scholar : PubMed/NCBI